These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Treatment of primary hyperlipoproteinaemia types, IIa, IIb, 3 and IV with clofibrate (author's transl)]. von Löwis P; Klemens UH Dtsch Med Wochenschr; 1973 Dec; 98(49):2328-33. PubMed ID: 4357927 [No Abstract] [Full Text] [Related]
5. Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia. Olsson AG; Orö L; Rössner S Atherosclerosis; 1975; 22(1):91-101. PubMed ID: 1098680 [TBL] [Abstract][Full Text] [Related]
6. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia. Patsch JR; Yeshurun D; Jackson RL; Gotto AM Am J Med; 1977 Dec; 63(6):1001-9. PubMed ID: 204188 [No Abstract] [Full Text] [Related]
7. Primary type V hyperlipoproteinaemia (mixed hyperlipaemia): successful response to dietary restriction and simfibrate. Teoh PC; Ransome GA Singapore Med J; 1974 Jun; 15(2):149-52. PubMed ID: 4370285 [No Abstract] [Full Text] [Related]
8. [Therapy of hyperlipemia and hyperuricemia with a combination of clofibrate and an extractive mucopolysaccharide complex]. Loizzi P; Terlizzi N Reumatismo; 1975; 27(1):157-62. PubMed ID: 184507 [No Abstract] [Full Text] [Related]
9. Effect of Al-chlorophenoxyisobutyrate (Alufibrate) on pyruvate metabolism and on the fate of very low density lipoprotein lipids in hyperlipidemic patients. Stähelin HB; Locher JT; Maier R Clin Chim Acta; 1974 Jul; 54(1):115-22. PubMed ID: 4367872 [No Abstract] [Full Text] [Related]
10. [Use of miskleron in ischemic heart disease with differing types of hyperlipoproteinemias]. Krivoruchenko IV; Nikul'cheva NG Kardiologiia; 1976 Jul; 16(7):71-5. PubMed ID: 185448 [TBL] [Abstract][Full Text] [Related]
11. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Miller NE; Nestel PJ Lancet; 1974 Oct; 2(7886):929-31. PubMed ID: 4138590 [No Abstract] [Full Text] [Related]
12. [Serum-lipid reducing principles--possibilities for treatment. 5. Indications for nicotinic acid and nicotinic acid derivatives]. Orö L Lakartidningen; 1970 Dec; 67():Suppl IV:63+. PubMed ID: 5511953 [No Abstract] [Full Text] [Related]
13. Treatment of essential hypercholesterolemia with clofibrate and nicotinic acid. Nordoy A; Gjone E Acta Med Scand; 1970 Dec; 188(6):487-90. PubMed ID: 5494813 [No Abstract] [Full Text] [Related]
14. [Field study on the decrease of lipids using etofibrate]. Schneider J; Haase W; Kaffarnik H Fortschr Med; 1976 May; 94(13):785-90. PubMed ID: 8362 [TBL] [Abstract][Full Text] [Related]
15. The coronary drug project. Design, methods, and baseline results. Circulation; 1973 Mar; 47(3 Suppl):I1-50. PubMed ID: 4570454 [No Abstract] [Full Text] [Related]
16. Secholex, Clofibrate and taurine in hyperlipidaemia. Howard AN; Evans RJ Atherosclerosis; 1974; 20(1):105-16. PubMed ID: 4376405 [No Abstract] [Full Text] [Related]
18. Treatment of hyperlipidemia. Levy RI; Morganroth J; Rifkind BM N Engl J Med; 1974 Jun; 290(23):1295-301. PubMed ID: 4363888 [No Abstract] [Full Text] [Related]
19. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. JAMA; 1973 Nov; 226(6):652-7. PubMed ID: 4356847 [No Abstract] [Full Text] [Related]